佐力药业:凌意生物的帕金森管线LY-N001研发工作正在持续推进中

格隆汇
Sep 07, 2025

佐力药业在机构调研时表示,凌意生物的帕金森管线LY-N001研发工作正在持续推进中,目前已完成主要的临床前研究工作。该管线针对的是与GBA1基因突变相关的帕金森亚型患者,未来目标是进行中美IND申报并开展临床研究及全球化市场的布局。凌意生物是一家专注于单基因遗传病源头创新药研发企业,定位为开发具有差异化优势的基因治疗药物。公司于2025年4月向凌意生物增资了2000万元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10